Sciogen, LLC
Publicly observedSan Jose, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Jose | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Sciogen, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | RGEHAJ63EJK5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Novel respiratory syncytial virus therapeutics targeting G-receptor binding
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2020Publicly observed
NIH SBIR/STTR award: Novel G protein-based RSV vaccine
USD 972,321.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.